Matteo Dugo

IRCCS Ospedale San Raffaele — Italy

Medicine · Health Sciences

33h-index3.5kcitations218works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(37), Cancer Genomics and Diagnostics(35), Estrogen and related hormone effects(34), Advanced Breast Cancer Therapies(34), HER2/EGFR in Cancer Research(30)

Publications218 total

Abstract PS2-09-09: Early on-treatment PD-L1 expression and stromal tumor infiltrating lymphocytes (sTILs) refine the prediction of EFS in the NeoTRIP trial
Clinical Cancer Research·2026
Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast Cancers
JCO Precision Oncology·2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer
npj Breast Cancer·2025Open Access
Correction: CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
Journal of Experimental & Clinical Cancer Research·2025· 1 citedOpen Access
Analysis of event-free survival (EFS) of stromal tumor infiltrating lymphocytes (sTILs), PD-L1 expression, and their early dynamics in the NeoTRIP trial.
Journal of Clinical Oncology·2025
72P Predictive value of spatially-derived archetypes and tertiary lymphoid structure signature in the NeoTRIP trial
ESMO Open·2025Open Access
Abstract 1712: CD36 enrichment in HER2+ mesenchymal stem cells potentiates therapy refractoriness in HER2+ breast cancer
Cancer Research·2025
Correction: Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts
Cell Death and Disease·2025· 1 citedOpen Access
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Nature Communications·2025· 2 citedOpen Access
From intrinsic to adaptive clusters in breast cancer
Cancer Cell·2025
Correction: Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b
Oncotarget·2025Open Access
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
Journal of Experimental & Clinical Cancer Research·2025· 11 citedOpen Access
Supplementary Data 3 from Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
2024Open Access
Supplementary Data 2 from Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
2024Open Access
Supplementary Data 1 from Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
2024Open Access
Data from Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma
2024Open Access
Data from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024· 1 citedOpen Access
Supplementary Figure S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Table S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
2024Open Access
page 1 of 11Next →

Frequent Co-authors

Loris De Cecco(18), Maria Grazia Daidone(10), Maurizio Callari(9), Elda Tagliabue(7), Silvana Canevari(6), Angela Greco(6), Maria Grazia Borrello(6), Tommaso A. Dragani(6), Elisabetta Vergani(5), Monica Rodolfo(5), Emanuela Minna(5), Paola Romeo(5), Marialuisa Sensi(5), Sara Noci(5), L. Santambrogio(5), Claudia Chiodoni(5), Claudio Tripodo(5), Mario P. Colombo(5), Giampaolo Bianchini(4), Silvana Pilotti(4)